Abstract
Mast cells and basophils are major effector cells in the immunoglobulin E (IgE)-dependent allergic reactions as well as in the innate immunity. They are distributed throughout the body and, upon allergen exposure, are stimulated via the high affinity IgE receptor (FcεRI) to release several pro-inflammatory mediators such as leukotrienes, immunoregulatory cytokines and histamine. FcεRI-mediated signaling is initiated by tyrosine phosphorylation of FcεRI subunits by Src family kinase Lyn, which is followed by an activation of Syk / Zap family kinase Syk. The activated kinases then in turn phosphorylate and activate other enzymes [phospholipase Cγ (PLCγ) isoforms, phosphatidylinositol-3 kinase (PI3K) isoforms, protein kinase C (PKC) isoforms, Brutons tyrosine kinase (Btk) and others], adaptors [linker for activation of T cells (LAT), Cbl, Grb2 and others] and GTP exchange factors / GTPases (Vav, Ras, Rho, and others), and subsequently induce the mobilization of stored and extracellular Ca2+. These and other biochemical events lead within seconds and minutes to the secretory response and later to the production of chemokines. This review is focused on the use of tyrosine kinase inhibitors specific for Src family kinases (PP1 / PP2, SU6656 and CT5269), Syk kinase (piceatannol, ER-27319 and BAY 61-3606) and Btk (terreic acid and LFM-A13) for a modulation of FcεRI-mediated signaling in mast cells. Potential use of the inhibitors in the treatment of inflammatory and allergy diseases as well as future directions in the development of highly specific tyrosine kinases inhibitors of new generations and their use in an intended modulation of mast cell signaling are discussed.
Keywords: mast cell, ige receptor, signal transduction, iyn, fyn, syk, btk, kinase inhibitors
Current Pharmaceutical Design
Title: Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases
Volume: 10 Issue: 15
Author(s): Petra Luskova and Petr Draber
Affiliation:
Keywords: mast cell, ige receptor, signal transduction, iyn, fyn, syk, btk, kinase inhibitors
Abstract: Mast cells and basophils are major effector cells in the immunoglobulin E (IgE)-dependent allergic reactions as well as in the innate immunity. They are distributed throughout the body and, upon allergen exposure, are stimulated via the high affinity IgE receptor (FcεRI) to release several pro-inflammatory mediators such as leukotrienes, immunoregulatory cytokines and histamine. FcεRI-mediated signaling is initiated by tyrosine phosphorylation of FcεRI subunits by Src family kinase Lyn, which is followed by an activation of Syk / Zap family kinase Syk. The activated kinases then in turn phosphorylate and activate other enzymes [phospholipase Cγ (PLCγ) isoforms, phosphatidylinositol-3 kinase (PI3K) isoforms, protein kinase C (PKC) isoforms, Brutons tyrosine kinase (Btk) and others], adaptors [linker for activation of T cells (LAT), Cbl, Grb2 and others] and GTP exchange factors / GTPases (Vav, Ras, Rho, and others), and subsequently induce the mobilization of stored and extracellular Ca2+. These and other biochemical events lead within seconds and minutes to the secretory response and later to the production of chemokines. This review is focused on the use of tyrosine kinase inhibitors specific for Src family kinases (PP1 / PP2, SU6656 and CT5269), Syk kinase (piceatannol, ER-27319 and BAY 61-3606) and Btk (terreic acid and LFM-A13) for a modulation of FcεRI-mediated signaling in mast cells. Potential use of the inhibitors in the treatment of inflammatory and allergy diseases as well as future directions in the development of highly specific tyrosine kinases inhibitors of new generations and their use in an intended modulation of mast cell signaling are discussed.
Export Options
About this article
Cite this article as:
Luskova Petra and Draber Petr, Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases, Current Pharmaceutical Design 2004; 10 (15) . https://dx.doi.org/10.2174/1381612043384538
DOI https://dx.doi.org/10.2174/1381612043384538 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Artificial Carriers: A Strategy for Constructing Antigenic/Immunogenic Conjugates
Current Topics in Medicinal Chemistry Effects of Culture Duration on Gene Expression of P450 Isoforms, Uptake and Efflux Transporters in Primary Hepatocytes Cultured in the Absence and Presence of Interleukin- 6: Implications for Experimental Design for the Evaluation of Downregulatory Effects of Biotherapeutics
Current Drug Metabolism Mutational Impact on the Interaction Between Human IL27 and gp130: In silico Approach for Defending HIV Infection
Current HIV Research CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples
Current Alzheimer Research Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Current Gene Therapy Synthesis of Prenylated Xanthones: An Overview
Current Organic Chemistry Genomics of Fungal Disease Resistance in Tomato
Current Genomics Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) The Blood-Central Nervous System Barriers Actively Control Immune Cell Entry into the Central Nervous System
Current Pharmaceutical Design The Adiponectin Signaling Pathway as a Novel Pharmacological Target
Mini-Reviews in Medicinal Chemistry Acute Inflammatory Gastric Aspiration-Related Lung Injury
Current Respiratory Medicine Reviews Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance
Current Topics in Medicinal Chemistry Preparation and Characterization of Binary and Ternary Complexes of Dihydroartremisinin with Hydroxypropyl-β-cyclodextrin, Palmitic acid and Polyvinylpyrrolidone K30
Current Pharmaceutical Analysis Nanotechnology in Ophthalmic Drug Delivery: A Survey of Recent Developments and Patenting Activity
Recent Patents on Nanomedicine p53 Regulation of Energy Metabolism and Mitochondria Regulation of p53 in Cancer Cells: An Insight into the Role of Manganese Superoxide Dismutase
Current Pharmaceutical Biotechnology MicroRNAs: A Novel Therapeutic Target for Schizophrenia
Current Pharmaceutical Design The TGF-β Signaling Pathway as a Pharmacological Target in a Hepatocellular Carcinoma
Current Pharmaceutical Design Successful Structure-Based Design of Recent p38 MAP Kinase Inhibitors
Current Topics in Medicinal Chemistry Inhibition of Monoamine Neurotransmitter Transporters and Central Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review-Update
Current Medicinal Chemistry - Central Nervous System Agents